IL-6 ELISA
- Known as:
- Interleukin-6 Enzyme-linked immunosorbent assay test
- Catalog number:
- kap1261
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Diasource
- Gene target:
- IL-6 ELISA
Related genes to: IL-6 ELISA
- Gene:
- CEBPB NIH gene
- Name:
- CCAAT enhancer binding protein beta
- Previous symbol:
- TCF5
- Synonyms:
- LAP, CRP2, NFIL6, IL6DBP, C/EBP-beta
- Chromosome:
- 20q13.13
- Locus Type:
- gene with protein product
- Date approved:
- 1991-02-27
- Date modifiied:
- 2018-02-23
- Gene:
- CEBPD NIH gene
- Name:
- CCAAT enhancer binding protein delta
- Previous symbol:
- -
- Synonyms:
- CRP3, CELF, C/EBP-delta, NF-IL6-beta
- Chromosome:
- 8q11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-24
- Date modifiied:
- 2018-02-23
- Gene:
- ENTPD6 NIH gene
- Name:
- ectonucleoside triphosphate diphosphohydrolase 6
- Previous symbol:
- CD39L2, IL6ST2
- Synonyms:
- NTPDase-6, dJ738P15.3
- Chromosome:
- 20p11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1998-03-20
- Date modifiied:
- 2019-02-28
- Gene:
- IL6 NIH gene
- Name:
- interleukin 6
- Previous symbol:
- IFNB2
- Synonyms:
- IL-6, BSF2, HGF, HSF
- Chromosome:
- 7p15.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2017-07-12
- Gene:
- IL6RP1 NIH gene
- Name:
- interleukin 6 receptor pseudogene 1
- Previous symbol:
- IL6RL1
- Synonyms:
- -
- Chromosome:
- 9q22.2
- Locus Type:
- pseudogene
- Date approved:
- 1991-08-18
- Date modifiied:
- 2014-11-19
Related products to: IL-6 ELISA
Related articles to: IL-6 ELISA
- Obstructive sleep apnea (OSA) is associated with chronic low-grade systemic inflammation. In cases of continuous positive airway pressure (PAP) failure, hypoglossal nerve stimulation (HNS) is a treatment option for OSA but its impact on systemic inflammation to date is unknown. Herein, we investigated changes in cytokines and endothelial markers before and after HNS. - Source: PubMed
Publication date: 2026/08/15
Pries RalphCai YiPlötze-Martin KirstinJelic SanjaFleckner JonasBruchhage Karl-LudwigSteffen Armin - Recombinant human type III collagen (rhCol III) is a non-animal-derived, biomimetic protein with notable regenerative potential. Nevertheless, its therapeutic efficacy in chronic inflammatory skin conditions such as atopic dermatitis (AD) remains insufficiently explored. This study aimed to evaluate the efficacy and safety of rhCol III as a topical therapeutic agent for AD. Utilizing an ovalbumin (OVA)-induced murine model of AD, topical application of rhCol III substantially ameliorated skin lesions, reduced scratching behavior and epidermal thickening, and suppressed mast cell infiltration and Th2 cytokines (IL-4, IL-13, and TSLP), while also demonstrating a decreasing trend in serum IgE levels. In vitro assays demonstrated that rhCol III inhibited the expression of IL-6, IL-1β, CXCL17 and CXCL22 in TNF-α and IFN-γ-stimulated HaCaT cells, confirming its anti-inflammatory properties. Long-term safety assessments revealed no structural abnormalities in the skin or major organs and no clinically relevant alterations in hematological parameters, bone mineral content (BMC), fat mass, or lean mass following 120 days of continuous topical application in mice. Preliminary clinical observations in infant patients with AD indicated that rhCol III was well tolerated, with observable symptom improvement, particularly in mild-to-moderate cases where topical rhCol III alone produced discernible therapeutic benefits. Collectively, these findings support the therapeutic potential and safety of rhCol III as a novel non-steroidal treatment strategy for AD. - Source: PubMed
Publication date: 2026/08/15
Liang JiayuanChen ShiyaoTao LiFu MaopingWang HongLi JikuiChen LiurongHan QinyuQiu BinghongLi ZongqiTan XiaofengWu HuijuanLi MingyuHuang LiuqingYang YamingXu LiYang YingLiao Qinyuan - Neuroinflammation has been identified as a causative factor of multiple neurological diseases. Microglia cells are the primary immune cells that regulate the neuroinflammation response. Hence, twenty-six 1,4,5,6-tetrahydrobenzo[2,3]oxepino[4,5-d]pyrimidine derivatives (BPMs) as anti-inflammatory molecules were designed and synthesized through two-step structural modification on the basis of the structure of the initial hit DL-1 from an in-house chemical library. The most potent compound 10a, modified with piperidine and benzamidine hydrochloride, was identified as the optimal candidate with strong anti-neuroinflammatory efficacies with no evident cellular cytotoxicity. Treatment with 10a efficiently attenuated LPS-induced neuroinflammation in microglia, as evidenced by reduced levels of inflammatory mediators, including ROS, NO, IL-1β, IL-6, TNF-α, and IL-18. Mechanistic studies demonstrated that 10a inhibits the NF-κB/NLRP3 pathway by suppressing phosphorylation of p65 and IκBα and decreasing NLRP3 protein expression. These results provide a promising strategy and good starting point for the development of a therapeutic candidate for neuroinflammation-related diseases. - Source: PubMed
Publication date: 2026/08/13
Xia De-LiChen YuXu Guang-SenHou Gui-Ge - Neurodegenerative diseases (NDs) impose a growing global burden on aging populations, characterized by progressive neuronal loss, synaptic dysfunction, and limited therapeutic options. Natural polysaccharides have attracted considerable attention as potential neuroprotective agents due to their diverse bioactivities and favorable safety profiles. - Source: PubMed
Publication date: 2026/08/04
Zhang YuchenYang ShuYuRan SitingDu MinruChen JiaqiCen MengdanGu YiLiao JiahuiLiu YunleZhang RuifenWang Jie - This study aims to investigate the potential protective effects of Achyranthes bidentata polysaccharides (ABPS) against severe traumatic brain injury (sTBI) and to elucidate the underlying mechanisms. - Source: PubMed
Publication date: 2026/08/15
Fang JingWeiChen XuxiaXie GuangMinLi KaiLv JunYing